Skip to main content
    RT @_Castillo_Pedro: BAFF & APRIL support B cell development, diff, survival.
    ALPN-303: Antagonist of both BAFF &am
    2 years 5 months ago
    BAFF & APRIL support B cell development, diff, survival. ALPN-303: Antagonist of both BAFF & APRIL 💠⬇️B cell fxn & Ab production,⬇️Plasma cells 💠⬇️UProt, dsDNA, renal immune complexes (mouse model) 💠Pending human studies https://t.co/kzVpUDuNWs #ACR21 Abst#1429 @RheumNow
    RT @KDAO2011: Novel way to treat inflammatory arthritis!
    A bioengineered probiotic bacterium, L. reuteri (LrS235) was f
    2 years 5 months ago
    Novel way to treat inflammatory arthritis! A bioengineered probiotic bacterium, L. reuteri (LrS235) was found effective to reduce inflammation and clinical signs of inflammation in rats with inflammatory arthritis. Abst # 1707 #ACR21 @rheumnow https://t.co/UC28yRlGYP
    RT @MeralElRamahiMD: Wager question that cemented the winners: @UTMB:
    ⭐️This monogenic disease can mimic Behcet's &a
    Wager question that cemented the winners: @UTMB: ⭐️This monogenic disease can mimic Behcet's & occurs d/t mutat in TNFAIP3. ➡️Haploinsufficiency A20 Congrats to the winners & all contestants, including the top 2 finalists: @MGHrheumatology & @EmoryUniversity! #ACR21 @RheumNow https://t.co/LZqsBKiPL8
    RT @AurelieRheumo: Anti-NETs antibodies in #COVID.
    1️⃣ correlate➖ w/ SpO2/FiO2 ratio (IgG r=-0.17 IgM r=-0.30
    2ï¸
    2 years 5 months ago
    Anti-NETs antibodies in #COVID. 1️⃣ correlate➖ w/ SpO2/FiO2 ratio (IgG r=-0.17 IgM r=-0.30 2️⃣correlate➕ w/ ⬆️D-dimer (IgG r=0.33 IgM r=0.19 3️⃣ ⬆️ in pts requiring MV In a study of 328 pts. Probably driving complement activation! #ACR21 #Abst1430 @RheumNow https://t.co/2MCrLueTzN
    RT @ericdeinmd: #ACR21 Abs:#1429: ALPN-303: Dual BAFF/APRIL antagonist for SLE:
    ⭐️Encouraging immunomodulatory activ
    2 years 5 months ago
    #ACR21 Abs:#1429: ALPN-303: Dual BAFF/APRIL antagonist for SLE: ⭐️Encouraging immunomodulatory activity and efficacy in animal models. ⬇️ Plasma cells and Ig secretions in vitro & vivo ⭐️Well-tolerated in animals w/o adverse events 🔥Phase 1 study in healthy volunteers! @Rheumnow
    The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest…
    RT @MeralElRamahiMD: Abst#0572: In US veterans w/ RA followed for 17 yrs, several cytokines+chemokines
    ⭐️Associated
    Abst#0572: In US veterans w/ RA followed for 17 yrs, several cytokines+chemokines ⭐️Associated w/ ↑ risk of incident MACE independent of typical CVD RF & RA activity & ⭐️Predicted MACE even if in LDA/remission WOW! We need to do better @ CVD risk strat! #ACRBest @RheumNow https://t.co/J74rRa9EQE
    RT @MeralElRamahiMD: ⭐️RA pts w/ high adipokines (fat-secreted proteins) have lower rates of LDA + remission indepen
    ⭐️RA pts w/ high adipokines (fat-secreted proteins) have lower rates of LDA + remission independent of b/l dz activity & BMI ⭐️↑ adipokines esp adiponectin, then more likely to need b/tsDMARD ➡️Adipokines may be prognostic biomarkers 4 refractory dz. Abst#0789 #ACR21 @RheumNow https://t.co/AFT22TzTFp